Back to top
more

ViewRay, Inc. (VRAY)

(Delayed Data from NSDQ)

$7.96 USD

7.96
4,991,682

+1.19 (17.58%)

Updated May 3, 2019 04:00 PM ET

After-Market: $7.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ViewRay (VRAY) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of -6.67% and 0.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 4.82% and 1.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will RxSight, Inc. (RXST) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

RxSight, Inc. (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate ViewRay (VRAY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of 6.25% and 0.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 2.33% and 0.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ViewRay (VRAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 13.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to gain momentum from a solid product portfolio and a strong General Surgery business. However, data security issues linger.

What Makes ViewRay (VRAY) a New Buy Stock

by Zacks Equity Research

ViewRay (VRAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of 12.50% and 13.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of -6.67% and 2.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Q4 Earnings Lag Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of -47.37% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Predict a 38% Upside in ViewRay (VRAY): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 38.4% upside potential for ViewRay (VRAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of 6.25% and 15.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment

by Zacks Equity Research

Accuray's (ARAY) latest agreement is likely to improve breast cancer treatment.

ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of -18.75% and 6.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ViewRay (VRAY) Stock Jumps 11.7%: Will It Continue to Soar?

by Zacks Equity Research

ViewRay (VRAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.

Strength Seen in ViewRay (VRAY): Can Its 13.8% Jump Turn into More Strength?

by Zacks Equity Research

ViewRay (VRAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.